Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Cory

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Blood|January 25, 2020
Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosisHai Vu Nguyen, Cassandra J Vandenberg, Ashley P Ng, et al.
Nature|February 23, 2002
BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytesPhilippe Bouillet, Jared F Purton, Dale I Godfrey, et al.
Blood|September 11, 2010
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also BimLina Happo, Mark S Cragg, Belinda Phipson, et al.
Cancer Cell|November 14, 2006
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedMark F van Delft, Andrew H Wei, Kylie D Mason, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2011
Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1Ben A Croker, Joanne A O'Donnell, Cameron J Nowell, et al.
Stem Cell Reports|October 29, 2021
CITED2 coordinates key hematopoietic regulatory pathways to maintain the HSC pool in both steady-state hematopoiesis and transplantationHannah Lawson, Louie N van de Lagemaat, Melania Barile, et al.
Cell Death and Differentiation|April 1, 2017
Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivoEmma M Carrington, Yifan Zhan, Jamie L Brady, et al.
Blood|April 28, 2012
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsDelphine Mérino, Seong L Khaw, Stefan P Glaser, et al.
Blood Cancer Discovery|May 7, 2024
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin AxisNicole D Vincelette, Xiaoqing Yu, Andrew T Kuykendall, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Blood|January 25, 2020
Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosisHai Vu Nguyen, Cassandra J Vandenberg, Ashley P Ng, et al.
Nature|February 23, 2002
BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytesPhilippe Bouillet, Jared F Purton, Dale I Godfrey, et al.
Blood|September 11, 2010
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also BimLina Happo, Mark S Cragg, Belinda Phipson, et al.
Cancer Cell|November 14, 2006
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedMark F van Delft, Andrew H Wei, Kylie D Mason, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2011
Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1Ben A Croker, Joanne A O'Donnell, Cameron J Nowell, et al.
Stem Cell Reports|October 29, 2021
CITED2 coordinates key hematopoietic regulatory pathways to maintain the HSC pool in both steady-state hematopoiesis and transplantationHannah Lawson, Louie N van de Lagemaat, Melania Barile, et al.
Cell Death and Differentiation|April 1, 2017
Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivoEmma M Carrington, Yifan Zhan, Jamie L Brady, et al.
Blood|April 28, 2012
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsDelphine Mérino, Seong L Khaw, Stefan P Glaser, et al.
Blood Cancer Discovery|May 7, 2024
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin AxisNicole D Vincelette, Xiaoqing Yu, Andrew T Kuykendall, et al.
Pageof 4